Andrew Gengos - 04 Jun 2026 Form 4 Insider Report for Turn Therapeutics Inc. (TTRX)

Reporting relationship: Director
Issuer ticker: TTRX
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 17:31:11 UTC
Prior SEC filing: 05 May 2026
Next SEC filing: 16 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Zuraiz Chaudhary, attorney-in-fact for Andrew Gengos

Key filing fact

Andrew Gengos filed Form 4 for Turn Therapeutics Inc. (TTRX) on 08 Jun 2026.

Key facts

This page summarizes Andrew Gengos's Form 4 filing for Turn Therapeutics Inc. (TTRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 Jun 2026, 17:31.

Change

Previous filing in this sequence was filed on 05 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001563623 Primary reporting owner

Gengos Andrew

Relationship: Director
Address: C/O TURN THERAPEUTICS INC., 250 N. WESTLAKE BLVD., WESTLAKE VILLAGE
Signature: /s/ Zuraiz Chaudhary, attorney-in-fact for Andrew Gengos
Signature date: 08 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TTRX transaction Derivative

Stock option (right to buy)

Award

Transaction value
Shares: +95,000
Change %
Price: $0.000000^*
Shares after: 95,000
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,000
Exercise price: $5.75
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.